Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intraosseous metaplastic meningioma: A case report.
Utsunomiya Y, Mori N, Matsui Y, Katsushima H, Hashimoto K, Furuta A. Utsunomiya Y, et al. Radiol Case Rep. 2021 Aug 26;16(11):3300-3303. doi: 10.1016/j.radcr.2021.07.080. eCollection 2021 Nov. Radiol Case Rep. 2021. PMID: 34484535 Free PMC article.
Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).
Fukuda M, Sakuma I, Wakasa Y, Funayama H, Kondo A, Itabashi N, Maruyama Y, Kamiyama T, Utsunomiya Y, Yamauchi A, Yoshii H, Yamada H, Mochizuki K, Sugawara M; J-SELECT study investigators. Fukuda M, et al. Among authors: utsunomiya y. Diabetes Ther. 2024 Jun;15(6):1403-1416. doi: 10.1007/s13300-024-01575-w. Epub 2024 Apr 24. Diabetes Ther. 2024. PMID: 38653904 Free PMC article.
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
Sugawara M, Fukuda M, Sakuma I, Wakasa Y, Funayama H, Kondo A, Itabashi N, Maruyama Y, Kamiyama T, Utsunomiya Y, Yamauchi A, Yoshii H, Yamada H, Mochizuki K; J-SELECT study investigators. Sugawara M, et al. Among authors: utsunomiya y. Diabetes Ther. 2023 Sep;14(9):1517-1535. doi: 10.1007/s13300-023-01438-w. Epub 2023 Jul 6. Diabetes Ther. 2023. PMID: 37410308 Free PMC article.
Differences in Characteristics Between Physical Frailty Assessments in Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Observational Study.
Tanaka Y, Hanada M, Kitagawa C, Suyama K, Shiroishi R, Rikitomi N, Tsuda T, Utsunomiya Y, Tanaka T, Shingai K, Yanagita Y, Kozu R. Tanaka Y, et al. Among authors: utsunomiya y. Int J Chron Obstruct Pulmon Dis. 2023 May 22;18:945-953. doi: 10.2147/COPD.S405894. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37251702 Free PMC article.
Isolation of OXA-48-like carbapenemase-producing Escherichia coli susceptible to piperacillin/tazobactam in a Japanese patient without a history of travel abroad.
Kaneko M, Masuda Y, Sawachika H, Shikata H, Moriyama C, Miura M, Yamamoto H, Nakamura T, Fukumoto K, Utsunomiya Y, Sakai K, Ito Y, Ujike A, Asano Y, Shinomiya H. Kaneko M, et al. Among authors: utsunomiya y. J Infect Chemother. 2023 May;29(5):530-533. doi: 10.1016/j.jiac.2023.01.024. Epub 2023 Feb 4. J Infect Chemother. 2023. PMID: 36746274
239 results